Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Aug 2;1(2):185-191.
doi: 10.1016/j.mayocpiqo.2017.07.002. eCollection 2017 Sep.

Cell-Based Therapy for Myocardial Dysfunction After Fontan Operation in Hypoplastic Left Heart Syndrome

Muhammad Y Qureshi  1 , Allison K Cabalka  1 , Shakila P Khan  2 , Donald J Hagler  1 , Dawit T Haile  3 , Bryan C Cannon  1 , Timothy M Olson  1 , Susana Cantero-Peral  4 , Allan B Dietz  5 , Darcie J Radel  5 , Nathan W Taggart  1 , Angela M Kelle  1 , Vilmarie Rodriguez  2 , Joseph A Dearani  6 , Patrick W O'Leary  1 ; Wanek Program Regenerative Medicine Pipeline
Collaborators, Affiliations
Case Reports

Cell-Based Therapy for Myocardial Dysfunction After Fontan Operation in Hypoplastic Left Heart Syndrome

Muhammad Y Qureshi et al. Mayo Clin Proc Innov Qual Outcomes. .

Abstract

Myocardial dysfunction after Fontan palliation for univentricular congenital heart disease is a challenging clinical problem. The medical treatment has a limited impact, with cardiac transplant being the ultimate management step. Cell-based therapies are evolving as a new treatment for heart failure. Phase 1 clinical trials using regenerative therapeutic strategies in congenital heart disease are ongoing. We report the first case of autologous bone marrow-derived mononuclear cell administration for ventricular dysfunction, 23 years after Fontan operation in a patient with hypoplastic left heart syndrome. The cells were delivered into the coronary circulation by cardiac catheterization. Ventricular size decreased and several parameters reflecting ventricular function improved, with maximum change noted 3 months after cell delivery. Such regenerative therapeutic options may help in delaying and preventing cardiac transplant.

Keywords: BM-MNCs, bone marrow–derived mononuclear cells; CK-MB, creatine kinase-MB; CMR, cardiac magnetic resonance; EF, ejection fraction; HLHS, hypoplastic left heart syndrome; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RV, right ventricle.

PubMed Disclaimer

References

    1. Pundi K.N., Pundi K., Driscoll D.J., et al. Heart transplantation after Fontan: results from a surgical Fontan cohort. Pediatr Transplant. 2016;20(8):1087–1092. - PubMed
    1. Assmus B., Honold J., Schächinger V., et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006;355(12):1222–1232. - PubMed
    1. Assmus B., Schächinger V., Teupe C., et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) Circulation. 2002;106(24):3009–3017. - PubMed
    1. Beitnes J.O., Gjesdal O., Lunde K., et al. Left ventricular systolic and diastolic function improve after acute myocardial infarction treated with acute percutaneous coronary intervention, but are not influenced by intracoronary injection of autologous mononuclear bone marrow cells: a 3-year serial echocardiographic sub-study of the randomized-controlled ASTAMI study. Eur J Echocardiogr. 2011;12(2):98–106. - PubMed
    1. Britten M.B., Abolmaali N.D., Assmus B., et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation. 2003;108(18):2212–2218. - PubMed

Publication types